Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.

Journal: Wellcome open research
Published Date: Oct 12, 2023

Abstract

BACKGROUND: Falciparum malaria remains a global health problem. Two vaccines, based on the circumsporozoite antigen, are available. RTS, S/AS01 was recommended for use in 2021 following the advice of the World Health Organisation (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization and WHO Malaria Policy Advisory Group (MPAG). It has since been pre-qualified in 2022 by the WHO. R21 is similar to RTS, S/AS01, and recently licensed in Nigeria, Ghana and Burkina Faso following Phase 3 trial results.

Authors

  • Samuel Sang
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Mehreen S Datoo
    The Jenner Instituite, Centre for Vaccinology and Tropical Medicine, University of Oxford and NIHR Biomedical Researcg Centre, Oxford, OX3 7LA, UK.
  • Edward Otieno
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Charles Muiruri
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Duncan Bellamy
    University of Oxford, The Jenner Instituite Laboratories, Old Campus Research Building (ORCB), Roosevelt Drive, OX3 7DQ, UK.
  • Emmaloise Gathuri
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Omar Ngoto
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Janet Musembi
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Sam Provstgaard-Morys
    University of Oxford, The Jenner Instituite Laboratories, Old Campus Research Building (ORCB), Roosevelt Drive, OX3 7DQ, UK.
  • Lisa Stockdale
    University of Oxford, The Jenner Instituite Laboratories, Old Campus Research Building (ORCB), Roosevelt Drive, OX3 7DQ, UK.
  • Jeremy Aboagye
    University of Oxford, The Jenner Instituite Laboratories, Old Campus Research Building (ORCB), Roosevelt Drive, OX3 7DQ, UK.
  • Daniel Woods
    University of Oxford, The Jenner Instituite Laboratories, Old Campus Research Building (ORCB), Roosevelt Drive, OX3 7DQ, UK.
  • Alison Lawrie
    The Jenner Instituite, Centre for Vaccinology and Tropical Medicine, University of Oxford and NIHR Biomedical Researcg Centre, Oxford, OX3 7LA, UK.
  • Racheal Roberts
    The Jenner Instituite, Centre for Vaccinology and Tropical Medicine, University of Oxford and NIHR Biomedical Researcg Centre, Oxford, OX3 7LA, UK.
  • Kelvias Keter
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Domtila Kimani
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Francis Ndungu
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Melissa Kapulu
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Irene Njau
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Benedict Orindi
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Katie J Ewer
    University of Oxford, The Jenner Instituite Laboratories, Old Campus Research Building (ORCB), Roosevelt Drive, OX3 7DQ, UK.
  • Adrian V S Hill
    The Jenner Instituite, Centre for Vaccinology and Tropical Medicine, University of Oxford and NIHR Biomedical Researcg Centre, Oxford, OX3 7LA, UK.
  • Philip Bejon
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.
  • Mainga Hamaluba
    KEMRI-Wellcome Trust Research Programme, Kilifi, Kilifi, 80108, Kenya.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals